Researchers have discovered how unusually long strands of RNA help colon cancer cells to avoid death, allowing unregulated growth.
Genomics has the potential to significantly improve the efficacy of drugs and develop targeted therapies.
Lurking quietly in the deep dark jungles of New Guinea are a group of lizards who share a rather striking feature: green blood. It’s a rare trait for vertebrates to have, but new insights into this strange blood could lead to innovative medical treatments.
Medigene has agreed to expand its nearly two-year-old strategic alliance with Bluebird bio, focusing on the research and development of T-cell receptor-modified T-cell immunotherapies (TCR-T) for the treatment of cancer.
Researchers have uncovered a number of proteins that could play a critical role propagating signals within cells that can lead to uncontrolled cell growth—one of the hallmarks of cancer.
Scientists have discovered the first example of a gene that is only found in one sex, and provides protection against cancers including an aggressive form of leukaemia.
A new chemotherapy regime has proved to shrink tumours twice as fast as in normal methods in patients with aggressive breast cancer carrying a faulty BRCA gene, according to a clinical trial.
Much of medicine is about information — the data that helps doctors make the right choices about our treatment. So how will the revolution in big data impact complex healthcare systems like the NHS?
A new cell-based medicine is offering hope for children suffering from incurable nerve tissue cancer, posing a dilemma for investors.
For the first time, scientists have revealed the essential genes for the most deadly human malaria parasite, Plasmodium falciparum. They have created new genomic techniques to analyse every gene in the parasite and determine which ones are indispensable.
Scientists have shown that boosting cells’ ability to process misfolded proteins could keep them from aggregating inside the cell, significantly delaying the onset of blindness in mice.
Denmark-based drugmaker Novo Nordisk has invested more in lobbying and doubled political donations since 2015.